ClinicalTrials.Veeva

Menu

Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1

V

Vrije Universiteit Brussel

Status

Completed

Conditions

Myotonic Dystrophy 1

Treatments

Diagnostic Test: Low frequency repetitive stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT05662150
Steinert study

Details and patient eligibility

About

The study design is a prospective cohort study. It aims to evaluate the neuromuscular junction in dystrophic myotonia 1 (DM 1) using low-frequency repetitive nerve stimulation (RNS) on several nerve-muscle pairs of the one side including proximal and distal muscles of upper and lower extremities. First, it will be investigated whether a decrement with 3 Hz stimulation, as described in literature, is reproducible in our patient population. If this is the case, it will be examined whether it is the consequence of a dysfunction of the neuromuscular junction or rather linked to a hypo-excitability of some muscle fibers due to myotonia. For this purpose, additional tests including short exercise test (to observe any decrement resulting from an inexcitability in myotonic muscle fibers) and needle EMG (for mapping myotonic discharges in the muscles tested with repetitive nerve stimulation) will be performed. Single fiber-EMG will not be provided in this study as an abnormal result does not necessarily indicate a dysfunction of the neuromuscular junction but could just as well be due to the muscular dystrophy in the context of DM1. Finally, it will be investigated if there is a correlation between the decrement

with 3 Hz stimulation and clinical signs as fixed muscle weakness (via Medical Research Counsil (MRC) scale, DM-activ scale [30]) and fatigue (via MG-ADL scale).

Enrollment

9 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

* genetically confirmed DM1

Exclusion criteria

  • minor age
  • auto-immune diseases
  • medical conditions involving the neuromuscular junction: (myasthenia gravis, Lambert-Eaton myasthenic syndrome, congenital myasthenia syndromes).

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

9 participants in 4 patient groups

Questionnaires
Active Comparator group
Description:
Patients with DM1 were asked to complete a questionnaire to rate a 25-item activity scale (DM1-Activ) and the Myasthenia Gravis Activity of Daily Life scale (MG-ADL) to rate their level of functional burden. For the DM1-Activ a score of 40 alludes no impairment and a score of 0 indicates the highest functional burden of physical activity. This scale has proven to be practical, reliable and valid. For the MG-ADL the total score ranges from 0 to 24, a score of 0 denotes no and 24 the highest functional burden. It should be noted that this scale is not adjusted for DM1. The rationale was to gain information about muscle fatigue and consequently the neuromuscular junction.
Treatment:
Diagnostic Test: Low frequency repetitive stimulation
grip strength via dynamometer
Active Comparator group
Description:
The isometric grip strength was tested by using a dynamometer. The subject will be asked to perform an increasing force against the dynamometer over a period of several seconds.
Treatment:
Diagnostic Test: Low frequency repetitive stimulation
short exercise test
Active Comparator group
Description:
The subject was asked to contract the ADM muscle as hard as possible in isometric conditions for 10 seconds. CMAP's was recorded 2 seconds after the end of the exercise and then every 10 seconds for 50 seconds.
Treatment:
Diagnostic Test: Low frequency repetitive stimulation
needle EMG
Active Comparator group
Description:
The electrical myotonia of each examined muscle was scored according to the Streiss and Sun scale.
Treatment:
Diagnostic Test: Low frequency repetitive stimulation

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems